Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Two dental companies go public inside a week, with very different results.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.